Nov. 8, 2016 | Prime Therapeutics
By the numbers: Managing accelerating autoimmune drugs costs across benefits is critical
Prime’s pharmacist researchers studied integrated trends in autoimmune drug use and spend, and presented their findings at the Academy of Managed Care Pharmacy (AMCP) 2016 Nexus event. Get the highlights — and learn what plan sponsors can do.
July 20, 2016 | Cathy Starner, PharmD, BCPS
America’s opioid epidemic: Part 5 — the future of safer opioid use
The opioid crisis is staggering, but steps are being taken in the right direction. What will tomorrow hold for safer opioid use?
July 12, 2016 | Cathy Starner
America’s opioid epidemic: Part 4 — fighting overuse through legislation, advocacy and political action
Solving the opioid crisis goes beyond the private sector. To drive meaningful change, health care, government and industry groups all have to work together.
July 8, 2016 | Cathy Starner
America’s opioid epidemic: Part 3 — strategies for curbing abuse
Combating the opioid crisis requires a full set of tools — and proof that they work. See how the research stacks up.
July 5, 2016 | Cathy Starner
America’s opioid epidemic: Part 2 — adding it up
To address the problem, we first have to gauge it. Prime’s researchers have worked to pinpoint who’s at highest risk for harm from controlled substances, such as opioids, and how this use potentially impacts the total cost of care.
June 28, 2016 | Cathy Starner
America’s opioid epidemic: Part 1 — diagnosing the problem
Opioid drugs are killing more Americans than ever. Every health care stakeholder must take action. Prime explores the ins and outs of opioid overuse and management in our latest five-part series.
April 29, 2016 | Kevin Bowen
4.5-year study finds diabetes and related drug costs surging
By 2050, as many as 1 in 3 adults in the United States will have diabetes. Coupled with drug price inflation, rising diabetic drug use has led to mounting costs for plan sponsors. To help measure the impact of rising use and costs, our team dove deep into Prime’s data to study diabetes prevalence, incidence and drug therapy.
Dec. 23, 2015 | Prime Therapeutics
REPORT: Defining parallels
As the Health Insurance Marketplace (HIM) matures into its second year, we’ve discovered a number of interesting parallels — and a few significant differences — in the way public exchange members use medicines and accumulate drug spend.
Aug. 15, 2015 | Prime Therapeutics
REPORT: 2014 prescription drug cost report — Defining dynamics
Prime Therapeutics (Prime) is pleased to announce our 2014 Report on prescription drug costs. This year, our definition of “drug trend” has evolved to reflect the change in net prescription costs. These costs offer the clearest picture of where costs start and how they compare.
June 1, 2015 | Prime Therapeutics
REPORT: Defining variance
Our new white paper, Defining variance, dives deeper into Health Insurance Marketplace data. In it, we explore differences in demographics, use and spend within the five different levels of coverage — identified as “metallic levels.” This analysis revealed more detailed insights and distinctions — and also a few surprises.
June 17, 2014 | Prime Therapeutics
REPORT: Prescription drug cost report — Looking back, moving forward
Prime Therapeutics is pleased to introduce our yearly look back at commercial pharmacy costs and spending trends from the previous year. We’ve renamed our annual trend publication to reflect the inclusion of net ingredient costs. Ingredient cost offers the clearest picture of where costs start and how they compare.
June 17, 2014 | Prime Therapeutics
INFOGRAPHIC: Spotlight on specialty
Spending on specialty medicines is growing quickly. Prime projects that ten years from today, these high-cost medicines could represent one quarter of all health care costs. How much do you know about these drugs? Our new infographic can quickly get you up to speed.